ADAPT SERON, OCULUS, and Jr study results build on VYVGART's approved gMG indication and show its potential as the first and only biologic therapy effective across MG subtypes ADHERE post hoc analysis ...
The phrase "claims evaluated" in this context refers only to research of how product information is presented across the official Steel Flow Pro pages and label disclosures. It does not mean the ...
A 2026 structured overview of VidaCalm's 18-ingredient hearing support formula, ingredient research context, safety considerations, and what consumers searching for tinnitus relief should verify ...
Title: Palazestrant, a CERAN, in combination with OP-3136, a KAT6 inhibitor, synergistically downregulates cell proliferation and metastasis related gene signatures Poster/Abstract: 2949 Session: ...
ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer ...
Findings support the ongoing Phase 1 clinical development of BBI-940, an oral, selective kinesin degrader, as a potential first-in-class therapy for select advanced or metastatic breast cancers SAN ...
Following the presentation on April 19, 2026 from 2:00–5:00 PM PT, the poster titled “PLK1 inhibitor onvansertib potentiates the antitumor efficacy of trastuzumab deruxtecan (T-DXd) and reverses its ...
Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters’ Option to Purchase ...
ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, announced ...
In preclinical studies, XTX601 demonstrated the potential to achieve a wide therapeutic index. XTX601 demonstrated protease-dependent activation and tumor cell killing in high- and low-expression ...
Under Nasdaq’s listing rules, the Company has 60 calendar days from receipt of the notice to submit a plan to regain compliance. If Nasdaq accepts the Company’s plan, Nasdaq may grant the Company an ...
In preclinical studies including patient-derived tumor xenograft models, PHST001 enhanced macrophage-mediated tumor control and prolonged survival in combination with chemotherapies and antibody-drug ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results